Comparison of emissions across tobacco products: A slippery slope in tobacco control

In this narrative review, we highlight the challenges of comparing emissions from different tobacco products under controlled laboratory settings (using smoking/vaping machines). We focus on tobacco products that generate inhalable smoke or aerosol, such as cigarettes, cigars, hookah, electronic cigarettes, and heated tobacco products. We discuss challenges associated with sample generation including variability of smoking/vaping machines, lack of standardized adaptors that connect smoking/vaping machines to different tobacco products, puffing protocols that are not representative of actual use, and sample generation session length (minutes or number of puffs) that depends on product characteristics. We also discuss the challenges of physically characterizing and trapping emissions from products with different aerosol characteristics. Challenges to analytical method development are also covered, highlighting matrix effects, order of magnitude differences in analyte levels, and the necessity of tailored quality control/quality assurance measures. The review highlights two approaches in selecting emissions to monitor across products, one focusing on toxicants that were detected and quantified with optimized methods for combustible cigarettes, and the other looking for product-specific toxicants using non-targeted analysis. The challenges of data reporting and statistical analysis that allow meaningful comparison across products are also discussed. We end the review by highlighting that even if the technical challenges are overcome, emission comparison may obscure the absolute exposure from novel products if we only focus on relative exposure compared to combustible products.

Key challenges for in vitro testing of tobacco products for regulatory applications: Recommendations for dosimetry

The Institute for In Vitro Sciences (IIVS) is sponsoring a series of workshops to develop recommendations for optimal scientific and technical approaches for conducting in vitro assays to assess potential toxicity within and across tobacco and various next-generation products (NGPs) including heated tobacco products (HTPs) and electronic nicotine delivery systems (ENDSs). This publication was developed by a working group of the workshop members in conjunction with the sixth workshop in that series entitled "Dosimetry for conducting in vitro evaluations" and focuses on aerosol dosimetry for aerosol exposure to combustible cigarettes, HTP, and ENDS aerosolized tobacco products and summarizes the key challenges as well as documenting areas for future research.

Deposition of Smoke Particles in Human Airways with Realistic Waveform

Exposure to toxic particles from smoke generated either from bush fire, stable burning, or direct smoking is very harmful to our health. The tiny particles easily penetrate deep into the lungs after exposure and damage the airways. Tobacco smoking causes the direct emission of 2.6 million tons of CO2 and 5.2 million tons of methane annually into the atmosphere. Nevertheless, it is one of the significant contributors to various respiratory diseases leading to lung cancer. These particles’ deposition in the human airway is computed in the present article for refining our understanding of the adverse health effects due to smoke particle inhalation, especially cigarette smoke. Until recently, little work has been reported to account for the transient flow pattern of cigarette smoking. Consideration of transient flow may change the deposition pattern of the particle. A high-resolution CT scan image of the respiratory tract model consisting of the oral cavity, throat, trachea, and first to sixth generations of the lungs helps predict cigarette smoke particle (CSP) deposition. With the same scan, a realistic geometric model of the human airways of an adult subject is used to simulate the transport of air and particle. The CSP deposition is determined at different locations from the oral cavity to the sixth generation of the bronchi. In addition, an unsteady breathing curve indicative of realistic smoking behavior is utilized to represent the breathing conditions accurately. The discrete phase model (DPM) technique is used to determine smoke particle deposition in the human airways. It is found that the deposition increases with the size of the smoke particle. Particles tend to deposit in the oral cavity around the bifurcation junction of the airways. The deposition fraction of CSP with the realistic waveform of smoking is found to be smaller compared to that during the stable flow condition. It is also observed that the fine particles (0.1–1.0 micron) escape to lower generations, leading to higher deposition of fine particles in the deeper airways. The outcome of the study is helpful for understanding smoke-related pulmonary complications.

State-of-the-art methods and devices for generation, exposure, and collection of aerosols from e-vapor products

E-vapor products (EVP) have become popular alternatives for cigarette smokers who would otherwise continue to smoke. EVP research is challenging and complex, mostly because of the numerous and rapidly evolving technologies and designs as well as the multiplicity of e-liquid flavors and solvents available on the market. There is an urgent need to standardize all stages of EVP assessment, from the production of a reference product to e-vapor generation methods and from physicochemical characterization methods to nonclinical and clinical exposure studies. The objective of this review is to provide a detailed description of selected experimental setups and methods for EVP aerosol generation and collection and exposure systems for their in vitro and in vivo assessment. The focus is on the specificities of the product that constitute challenges and require development of ad hoc assessment frameworks, equipment, and methods. In so doing, this review aims to support further studies, objective evaluation, comparison, and verification of existing evidence, and, ultimately, formulation of standardized methods for testing EVPs.